RESUMO
We evaluated the seroprevalence of measles antibody and response to measles reimmunization in 590 previously vaccinated adolescents and young adults; 263 were seronegative. To differentiate between primary and secondary vaccine failure, anti-measles IgM and IgG titres were assessed again 2-4 weeks after revaccination in 144 (105 seronegative, 39 seropositive) individuals: 75 seronegative participants responded to revaccination anamnestically (P < 0.001) and developed immunity, 11 also showed IgM response (probably primary vaccine failure); 38 seropositive participants remained seroprotected without significant increase in antibody titre (P = 0.577). Primary vaccine failure was 4.7%; secondary vaccine failure was 27.1%. After revaccination, 87.3% were seroprotected.
Assuntos
Imunização Secundária/métodos , Vacinação em Massa/métodos , Vacina contra Sarampo/imunologia , Sarampo/epidemiologia , Sarampo/prevenção & controle , Adolescente , Adulto , Assistência ao Convalescente , Anticorpos Antivirais/sangue , Ensaio de Imunoadsorção Enzimática , Feminino , Necessidades e Demandas de Serviços de Saúde , Humanos , Esquemas de Imunização , Imunoglobulina G/sangue , Imunoglobulina M/sangue , Irã (Geográfico)/epidemiologia , Masculino , Programas de Rastreamento/métodos , Sarampo/sangue , Sarampo/imunologia , Vírus do Sarampo/imunologia , Vigilância da População , Estudos Soroepidemiológicos , Falha de TratamentoRESUMO
We evaluated the seroprevalence of measles antibody and response to measles re-immunization in 590 previously vaccinated adolescents and young adults; 263 were seronegative. To differentiate between primary and secondary vaccine failure, anti- measles IgM and IgG titres were assessed again 2- 4 weeks after revaccination in 144 [105 seronegative, 39 seropositive] individuals: 75 seronegative participants responded to revaccination anamnestically [P < 0.001] and developed immunity 11 also showed IgM response [probably primary vaccine failure immunity]; 38 seropositive participants, remained seroprotected without significant increase in antibody titre [P = 0.577]. Primary vaccine failure was 4.7%; secondary vaccine failure was 27.1%. After revaccination, 87.3% were seroprotected
